Rio Tinto Sell Alcan Composites

Rio Tinto has entered into an agreement to sell Alcan Composites, part of the Alcan Engineered Products division, to Schweiter Technologies for a total consideration of US$349 million. The transaction is expected to close by the end of the year, following completion by the parties of various conditions precedent to closing, including regulatory processes and employee consultations.

Last week, Rio Tinto announced the sale of 56 per cent of the Alcan Engineered Products Cable business to Platinum Equity.

"In the last three months we have made significant inroads into divesting the downstream assets acquired with Alcan, including offers or agreed sales for the majority of Alcan Packaging and Cable," said Guy Elliott, finance director, Rio Tinto. "Schweiter Technologies is well placed to successfully develop the Composites business, and we are realising further value for Rio Tinto shareholders."

Schweiter Technologies is a Swiss listed company focusing on the manufacture of textile and semiconductor machinery. The business currently consists of the SSM Textile Machinery and Ismeca Semiconductor divisions, and the intention is that Composites will form a third standalone division within the group, consistent with Schweiter Technologies' strategy of acquiring and running companies that are market leaders in their chosen segments.

Alcan Composites is a world leading sandwich composite materials manufacturing business focused on the display, architecture, and wind energy sectors. Headquartered in Sins, Switzerland, it operates 16 plants in Europe (Germany and Switzerland), the USA, South America, China and India and employs approximately 3,000 people. Its leading brands include Airex, Baltek, Dibond, Gator, Kapa, Forex, Sintra and Fome-Cor and the business serves a wide range of end-markets.

In the last 12 months to August 2009 Composites achieved sales of US$649 million and an EBITDA of US$54 million. All figures are unaudited and on a pro forma basis.

Since February 2008, Rio Tinto has announced asset sales of US$7 billion including the Composites sale. In addition, Rio Tinto received a binding offer from Amcor in August 2009 for US$2.025 billion for Alcan Packaging global pharmaceuticals, global tobacco, food Europe and food Asia divisions. During 2008, Rio Tinto announced divestments comprising the Greens Creek mine in Alaska for US$750 million, its interest in the Cortez operation in Nevada for US$1.695 billion and the Kintyre uranium project in Western Australia for US$495 million.

Announced transactions in 2009 comprise the Group's interest in the Ningxia aluminium smelter in China for US$125 million, its Jacobs Ranch coal mine in the United States for US$761 million, Alcan Packaging Food Americas to Bemis Inc for US$1.2 billion, the Corumba iron ore mine in Brazil and associated river logistics for US$750 million and the Potasio Rio Colorado potash project in Argentina and the Regina exploration assets in Canada for US$850 million.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Amcor PLC. (2019, February 10). Rio Tinto Sell Alcan Composites. AZoM. Retrieved on April 19, 2024 from https://www.azom.com/news.aspx?newsID=18995.

  • MLA

    Amcor PLC. "Rio Tinto Sell Alcan Composites". AZoM. 19 April 2024. <https://www.azom.com/news.aspx?newsID=18995>.

  • Chicago

    Amcor PLC. "Rio Tinto Sell Alcan Composites". AZoM. https://www.azom.com/news.aspx?newsID=18995. (accessed April 19, 2024).

  • Harvard

    Amcor PLC. 2019. Rio Tinto Sell Alcan Composites. AZoM, viewed 19 April 2024, https://www.azom.com/news.aspx?newsID=18995.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.